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E-mail address: lyu@wfubmc.edu (L. Yu).The polytopic transmembrane protein, Niemann–Pick C1-Like 1 (NPC1L1), is enriched in the apical
membrane of small intestine absorptive enterocytes where it mediates extracellular sterol transport
across the brush border membrane. It is essential for intestinal sterol absorption and is the molec-
ular target of ezetimibe, a potent cholesterol absorption inhibitor that lowers blood cholesterol in
humans. NPC1L1 is also highly expressed in human liver. The hepatic function of NPC1L1 may be
to limit excessive biliary cholesterol loss. NPC1L1-dependent sterol uptake seems to be a clathrin-
mediated endocytic process and is regulated by cellular cholesterol content. Recently, NPC1L1 inhi-
bition has been shown to have beneﬁcial effects on components of the metabolic syndrome, such as
obesity, insulin resistance, and fatty liver, in addition to atherosclerosis.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Elevated blood cholesterol levels contribute to atherosclerotic
coronary heart disease. Cholesterol homeostasis in the body is
mainly balanced by its intestinal absorption, endogenous biosyn-
thesis, and biliary/intestinal excretion. While much is known about
cholesterol biosynthesis and its regulation [1,2], the mechanisms
for cholesterol absorption and excretion were poorly understood
until recently. Early in the 21st century, the heterodimer of two
ATP-binding cassette (ABC) transporters G5 and G8 (ABCG5/G8)
was demonstrated to be crucial for biliary and perhaps intestinal
secretion of cholesterol and non-cholesterol sterols [3–6]. In
2004, Niemann–Pick C1-Like 1 (NPC1L1) was shown to play an
essential role in intestinal cholesterol absorption [7]. Discovery of
NPC1L1 has greatly enhanced our understanding of whole-body
cholesterol metabolism, and speciﬁcally intestinal cholesterol
absorption, a process that can be blocked by the potent cholesterol
absorption inhibitor ezetimibe. A growing body of data is implicat-
ing a role for NPC1L1 and NPC1L1-dependent intestinal cholesterol
absorption in metabolic diseases such as non-alcoholic fatty liver
disease, insulin resistance, diabetes, and obesity in addition to ath-
erosclerotic coronary heart disease. This review will examine the
recent studies on the role of NPC1L1 in sterol transport and
diseases.chemical Societies. Published by E2. NPC1L1 as an intestinal cholesterol transporter
Cholesterol in the intestinal lumen is mainly derived from bil-
iary secretion and dietary intake. Intestinal epithelial sloughing
and direct secretion of cholesterol from enterocytes may also par-
tially contribute to the luminal cholesterol pool where cholesterol
is solubilized in micelles enriched with bile acids and phospholip-
ids. Intestinal cholesterol absorption is an integrated process,
including at least three major steps: (1) solubilization in micelles,
(2) transport across the apical membrane of absorptive entero-
cytes, and (3) mobilization to chylomicrons for secretion into
the lymph and blood via the basolateral membrane of enterocytes.
In humans, the fractional intestinal cholesterol absorption ranges
from 29% to 80% [8]. Despite this large variation, intestinal choles-
terol absorption is a major pathway controlling whole-body cho-
lesterol homeostasis, and therefore represents an attractive drug
target.
The search for intestinal cholesterol absorption inhibitors led to
the development of ezetimibe (commercially known as Zetia) by
Schering-Plough Research Institute and Merck Co. (NJ, USA). The
drug was approved by the US Food and Drug Administration to
treat hypercholesterolemic patients before its molecular target
was known. Because ezetimibe inhibition of intestinal cholesterol
absorption in animals results in a compensatory upregulation of
endogenous cholesterol biosynthesis [9,10], the drug is often used
in combination with a statin that blocks cholesterol synthesis by
inhibiting the rate-limiting enzyme 3-hydroxy-3-methyl-glutaryl-
CoA reductase [11]. Ezetimibe monotherapy or coadministration
with a statin efﬁciently lowers plasma total cholesterol andlsevier B.V. All rights reserved.
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mechanism for cholesterol transport across the apical membrane
of enterocytes was thought to be passive diffusion before the dis-
covery of ezetimibe [12]. The pharmacological potency of ezetim-
ibe demonstrated that speciﬁc proteins rather than passive
diffusion are implicated in this process. In the search for molecular
targets of ezetimibe, Altmann and colleagues at Schering-Plough
Research Institute (NJ, USA) identiﬁed NPC1L1, an apically-local-
ized sterol transporter in the small intestine, using a genome-wide
bioinformatics screening approach [7]. They further showed that
genetic deletion of NPC1L1 in mice reduces intestinal cholesterol
absorption to the levels seen in ezetimibe-treated mice, and that
ezetimibe treatment results in no further reduction of intestinal
cholesterol absorption in mice lacking NPC1L1 [7,9]. This study
clearly demonstrated that NPC1L1 is in the ezetimibe-sensitive
pathway and deﬁnitively established the critical role of NPC1L1
in intestinal cholesterol absorption.
3. Conserved domains in NPC1L1 protein
NPC1L1 is a polytopic transmembrane protein of 1332 amino
acids. It shares sequence homology with Niemann–Pick C1
(NPC1) [13], a protein that is mutated in the lipid storage disorder
Niemann–Pick disease type C1 [14,15] (Fig. 1). Like its homolog,
NPC1L1 was predicted to have a typical signal peptide and 13
membrane-spanning domains [7,13,16–18], and this prediction is
consistent with recent experimental data [19]. NPC1L1 also has a
conserved N-terminal ‘‘NPC1” domain, and extensive N-linked gly-Fig. 1. Amino acid sequence and predicted topological structure of human Niemann–Pic
residues. Two potential YXXØ endocytic motifs are outlined in blue squares. Residues in d
extensive N-linked glycosylation sites which are highlighted in green. The N-terminal 21cosylation sites [7,13,17] (Fig. 1). Interestingly, the crystal struc-
ture of the cysteine-rich N-terminal domain of NPC1 exposed a
sterol-binding pocket [20]. Because the N-terminus of NPC1L1
encompasses a similar cysteine-rich globular domain, it is likely
that this region also binds sterols [21].
Five of the 13 membrane-spanning helices of NPC1L1 constitute
a predicted sterol sensing domain (SSD) encompassing 180 ami-
no acids [7,13] (Fig. 1). This SSD is conserved in several other mem-
brane proteins involved in cholesterol transport, metabolism, or
regulation [22], including NPC1 [13–15]; 3-hydroxy-3-methylglut-
aryl CoA reductase, the rate-limiting enzyme in the cholesterol bio-
synthetic pathway [1,23]; sterol regulatory element-binding
protein (SREBP)-cleavage activating protein (SCAP), a protein that
controls the transport and proteolytic activation of SREBPs, which
are membrane-bound transcription factors governing the synthesis
of cholesterol and other lipids [1,2,23]; and Patched, a membrane
receptor for the cholesterol-linked signaling peptide Hedgehog
[24]. The functional signiﬁcance of the SSD in these proteins re-
mains elusive.
Biochemical evidence suggests that the SSD may be involved in
sterol binding. For example, cholesterol was shown to directly bind
to the puriﬁed SSD-containing membrane region of SCAP through
receptor–ligand interaction; thus, SCAP was deﬁned as a receptor
for free cholesterol in the endoplasmic reticulum [25]. The require-
ment of a functional SSD for NPC1 binding to a photo-activatable
cholesterol analog was reported years ago [26], although a sterol-
binding pocket was recently localized to its cysteine-rich N-termi-
nal domain [20].k C1-Like 1 (NPC1L1). The conserved N-terminal ‘‘NPC1” domain is shown with red
ark circles denote the sterol-sensing domain. The luminal portion of NPC1L1 also has
amino acids are assumed to be the signal peptide and are not shown in this ﬁgure.
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regulated by cellular cholesterol content [22,27]. The SSD may reg-
ulate sterol-dependent trafﬁcking of these proteins. In animals,
NPC1L1 mainly resides at the apical membrane of enterocytes
and hepatocytes [7,28–31], a membrane region that is exposed to
unesteriﬁed free cholesterol. In cultured hepatoma cells, we
showed that NPC1L1 can localize to both the plasma membrane
and endocytic recycling compartment (ERC), mirroring the distri-
bution of free cholesterol in the cell, and its subcellular location
is regulated by cellular cholesterol availability [29]. Under normal
culture conditions, NPC1L1 is enriched in the ERC, which has been
shown to be a cholesterol-rich region of cells [32]. When choles-
terol is depleted in cultured cells with cyclodextran, NPC1L1 is
translocated to the apical subdomain of the plasma membrane
from the ERC. Conversely, when cholesterol is replenished, NPC1L1
is internalized, which is coupled with cellular cholesterol uptake
[29]. These ﬁndings are further supported by subsequent cell biol-
ogy studies using the same cell line [33]. Future studies are re-
quired to examine the role of NPC1L1’s SSD in the sterol-
regulated trafﬁcking of NPC1L1.
4. Molecular mechanisms for NPC1L1-dependent cholesterol
uptake
Several pieces of evidence suggest that the molecular mecha-
nism for NPC1L1-dependent cholesterol uptake may be choles-
terol-regulated clathrin-mediated endocytosis [29,33–35]. First,
NPC1L1 protein cycles between the cell surface and intracellularFig. 2. Proposed model of NPC1L1-dependent cholesterol uptake. NPC1L1 is enriched
cholesterol is recruited to the NPC1L1-containing plasma membrane microdomain by
threshold in the microdomain, it is sensed by NPC1L1’s SSD, which then triggers NPC1
cholesterol-containing membrane microdomain via clathrin-mediated endocytosis. Tw
many plasma membrane proteins via interaction with the l subunit of AP2 are highl
endosome and/or the endocytic recycling compartment, freeing NPC1L1 to be recycled b
cholesterol deprivation. Ezetimibe interacts with the second extracellular loop of NPC1L1
uptake.compartments in a cholesterol-dependent manner [29]. Second,
this cholesterol-regulated NPC1L1 translocation is coupled to cho-
lesterol uptake [29], which can be blocked by potassium depletion
[34], a treatment that inhibits clathrin-mediated endocytosis [36].
Third, caveolin-1, a structural protein of caveolae, is dispensable
for intestinal cholesterol absorption [37], demonstrating that cav-
eolae-mediated endocytosis is not the cellular basis for NPC1L1-
dependent cholesterol uptake. Fourth, NPC1L1 co-immunoprecipi-
tates with the l2 (mu2) subunit of the adaptor protein (AP) com-
plex AP2, and with clathrin heavy chain [33], two proteins
necessary for clathrin-dependent endocytosis.
A cytosolic tyrosine-based sorting signal YXXØ (tetrapeptide)
has been shown to facilitate the clathrin-mediated endocytosis of
many plasma membrane proteins via interaction with the l sub-
unit of AP2 [38]. In YXXØ motif, the tyrosine (Y) residue is func-
tionally indispensable. The Ø represents a residue with a bulky
hydrophobic side chain. The X residues vary highly. The endocytic
YXXØ signals are most often 10–40 residues away from the mem-
brane-spanning domains, but not at the carboxy-termini of pro-
teins [38]. Intriguingly, NPC1L1 has two potential YXXØ motifs
(Y721QRL and Y836APF) [21] (Figs. 1 and 2). The Y721QRL sequence
is within the SSD region and the two motifs are conserved in
NPC1L1 proteins from drosophila to mammals, implying their
functional signiﬁcance. It is tempting to speculate that one of these
motifs regulates NPC1L1-dependent cholesterol uptake through
interaction with proteins of the clathrin-mediated endocytic
pathway in a cholesterol-dependent manner (Fig. 2). In this case,
NPC1L1 appears to function as a free cholesterol receptor in theat the plasma membrane when cellular cholesterol levels are low. Extracellular
binding to NPC1L1 or other mechanisms. When cholesterol content increases to a
L1 protein conformational changes and subsequent internalization of the NPC1L1/
o potential YXXØ motifs known to facilitate the clathrin-mediated endocytosis of
ighted in blue squares. NPC1L1 and its sterol cargo are dissociated in the sorting
ack to the plasma membrane to take up additional cholesterol, particularly during
, causing conformational changes of NPC1L1 protein, thereby inhibiting cholesterol
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cholesterol in the endoplasmic reticulum [25].
How does NPC1L1 efﬁciently transport cholesterol into a cell?
One plausible possibility is that NPC1L1 recruits extracellular free
cholesterol through its N-terminus to its cell membrane location,
which may create a RAFT-like plasma membrane microdomain.
The cholesterol content in this microdomain is sensed by NPC1L1’s
SSD. When cholesterol is enriched to a threshold in this membrane
region, the entire microdomain is endocytosed to facilitate choles-
terol uptake.
For intestinal cholesterol absorption, free cholesterol has to be
sorted to the endoplasmic reticulum for incorporation into choles-
terol ester, which will then be packaged into chylomicrons. How is
NPC1L1-derived free cholesterol sorted to the endoplasmic reticu-
lum? Is it sorted out directly from the early endosome or from the
endocytic recycling compartment?What will carry it to its destina-
tion? Answers to these questions would greatly enhance the
molecular understanding of intestinal cholesterol absorption.
Based on cell culture studies [29,33–35], NPC1L1 sorted to the
endocytic recycling compartment can be recycled back to the cell
surface, a process that appears to involve an endocytic recycling
triple complex consisting of the microﬁlament-interacting motor
myosin Vb, the small GTPase Rab11a, and the adaptor Rab11-
FIP2 [39]. Thus, it is likely that free cholesterol is dissociated from
NPC1L1 in the endocytic recycling compartment or earlier endo-
cytic stages.5. Substrate speciﬁcity of NPC1L1
Evidence indicates that NPC1L1 can absorb both animal and
plant sterols because both sterol classes are dramatically reduced
in NPC1L1 knockout mice [7,9,40,41] and in ezetimibe-treated
sitosterolemic patients [42] and mice [43]. But NPC1L1 does not
seem to absorb all sterols equally. Uptake of sitosterol versus cho-
lesterol from various donors is signiﬁcantly lower in cells over-
expressing NPC1L1 [33,34,44], suggesting that NPC1L1 has a great-
er afﬁnity for cholesterol than sitosterol, a major plant-derived ste-
rol in the diet. It was thought that the heterodimer ABCG5/G8 was
the major discriminator of animal-derived sterols from plant-de-
rived phytosterols because mutations in these genes cause a genet-
ic disorder, sitosterolemia that is characterized by massive
accumulation of phytosterols in the body [3,4]. However, the rank
order of intestinal sterol absorption rates (cholesterol > cholesta-
nol > campesterol > sitosterol) is maintained in mice lacking
ABCG5/G8 [5,45]. This ﬁnding implies that the sterol efﬂux trans-
porter ABCG5/G8 does not discriminate sterols, but rather, the ste-
rol inﬂux transporter NPC1L1’s afﬁnity for different sterols may
largely contribute to the rank order of the individual sterols’ intes-
tinal absorption rates.
Whether NPC1L1 transports other substrates remains contro-
versial. NPC1L1, like its homolog NPC1, shares similarity with the
resistance-nodulation-division (RND) family of prokaryotic perm-
eases that are involved in the efﬂux of lipophilic drugs, detergents,
fatty acids, bile acids, metal ions, and dyes from the cytosol of bac-
teria [16,46], suggesting a potential role of NPC1L1 in the transport
of other substrates. In one study using Caco-2 cells, NPC1L1 over-
expression appears to facilitate a-tocopherol (vitamin E) uptake
in an ezetimibe-sensitive manner, but not the uptake of retinol
(vitamin A) or cyclosporin A [47]. In this same study, rats treated
with ezetimibe showed reduced absorption of radiolabeled a-
tocopherol. But the serum concentrations of vitamin E do not differ
signiﬁcantly in steady state in ezetimibe-treated patients [48]. The
physiological signiﬁcance of NPC1L1 in vitamin E absorption re-
mains elusive. An earlier study showed that ezetimibe does not in-
hibit intestinal absorption of triglyceride and vitamins A and D inrodents [49]. Using a very sensitive method to measure intestinal
fat absorption, a group recently demonstrated a modest, but signif-
icant reduction in intestinal absorption of long chain saturated
fatty acids in NPC1L1 knockout mice or ezetimibe-treated mice
on a high fat diet [50]. How an intestinal cholesterol transporter
inﬂuences fatty acid absorption, and whether this phenomenon
can be recapitulated in animals fed other diets, is uncertain.
6. NPC1L1 as the molecular target of ezetimibe
The fact that NPC1L1 is involved in an ezetimibe-sensitive
pathway for cholesterol uptake is clearly documented
[7,9,18,28,29,33,34,44,51]. However, whether NPC1L1 is the direct
molecular target of the drug has been controversial [52–55].
NPC1L1 overexpression in cultured cells promotes cholesterol up-
take and this NPC1L1-dependent cholesterol uptake can be blocked
by ezetimibe [29,33,34,44]. Garcia-Calvo and colleagues [28] found
that isotope-labeled ezetimibe binds the enterocyte brush border
membrane vesicles of wild-type mice, but not NPC1L1 knockout
mice. In addition, the degree of ezetimibe inhibition correlates
with NPC1L1 binding afﬁnity to ezetimibe across many species
[18]. In humans, NPC1L1 sequence variations are associated with
sterol absorption rates, LDL-C levels [56] and LDL-C response to
ezetimibe therapy [57–59]. Importantly, ezetimibe was recently
shown to directly bind NPC1L1, and the location of ezetimibe bind-
ing to NPC1L1 was mapped to the second extracellular loop of
NPC1L1 [60] (Fig. 1). Taken together, these data support the notion
that NPC1L1 is the molecular target of ezetimibe. Ezetimibe bind-
ing to NPC1L1 may result in NPC1L1 protein conformational
changes, thereby disturbing NPC1L1 and free cholesterol
interactions and ultimately inhibiting cholesterol-induced NPC1L1
endocytosis [29,33].7. Hepatic NPC1L1 and canalicular re-uptake of cholesterol
NPC1L1 is highly expressed in the small intestine across mam-
malian species [7,40]. The regulation of NPC1L1 expression is lar-
gely unknown and data on this topic are inconsistent [61–78].
Readers interested in regulation of NPC1L1 expression are referred
to references listed above and recent reviews [79,80].
The tissue pattern of NPC1L1 expression differs among species.
Although rodent livers express only trivial amounts of NPC1L1
[65], NPC1L1 is readily detectable in human livers [7,30,40]. Why
human livers express NPC1L1 remains unclear. In the small intes-
tine, NPC1L1 transports biliary and dietary cholesterol from the
intestinal lumen into the enterocyte to facilitate cholesterol
absorption. In the liver, NPC1L1 localizes to the bile canalicular
membrane [29,30]. We found that human NPC1L1, when transgen-
ically over-expressed in the mouse liver, is localized to the bile
canalicular membrane [30]. In these transgenic animals, choles-
terol levels in the bile are dramatically reduced with no effects
on the hepatic expression of the canalicular cholesterol efﬂux
transporter ABCG5/G8 [30]. This ﬁnding supports the idea that he-
patic NPC1L1 may counterbalance ABCG5/G8-mediated biliary
secretion of sterols by transporting sterols in the bile canaliculus
back to hepatocytes (Fig. 3). This mechanism may have evolved
to protect against excessive biliary loss of cholesterol, a crucial
structural component of the cell membrane. The fact that the
two opposing sterol transporters, NPC1L1 and ABCG5/G8, evolved
in the same subcellular location of both enterocytes and hepato-
cytes is intriguing, highlighting the importance of sterol balance
in life.
An alternative explanation for why NPC1L1 resides at the cana-
licular membrane of human instead of murine hepatocytes may be
attributable to the difference in bile acid hydrophobicity between
Fig. 3. Role of NPC1L1 and ABCG5/G8 in enterohepatic cholesterol recirculation. Biliary and dietary sterols are mixed in the gut lumen and solubulized by bile acids (BA) and
phospholipids (PL) to formmixed micelles. NPC1L1 absorbs sterols, including free cholesterol (FC), from these mixed micelles at the apical surface of the enterocyte. Sterols in
enterocytes can be pumped out to the gut lumen by the action of the heterodimeric ATP-binding cassette transporters G5 and G8 (ABCG5/G8), or can be esteriﬁed by acyl-
coenzyme A: cholesterol acyltransferase 2 (ACAT2) to yield cholesteryl ester (CE) for assembly into chylomicrons for secretion into lymph. In the hepatocyte, ABCG5/G8 at the
canalicular membrane pumps free cholesterol into the bile canaliculus. This action is opposed by NPC1L1, which reabsorbs the FC back into the hepatocyte. Thus, in both the
enterocyte and hepatocyte, sterol efﬂux by ABCG5/G8 is opposed by NPC1L1-dependent sterol inﬂux.
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compared to those from rodents. Hydrophobic bile acids are cyto-
toxic and can cause liver injury and cholestasis. Membrane choles-
terol content could be an important factor that renders the
canalicular membrane resistant to the cytotoxic effects of concen-
trated bile acids [81]. Thus, canalicular NPC1L1 protein, by retriev-
ing free cholesterol in the canalicular bile back to the canalicular
membrane may protect hepatocytes against cytotoxicity induced
by hydrophobic bile acids concentrated in human bile.
8. Hepatic NPC1L1 as a target of ezetimibe: good or bad?
When liver-speciﬁc NPC1L1 transgenic mice are treated with
ezetimibe, biliary cholesterol excretion is restored [30]. This ﬁnd-
ing demonstrated that hepatic NPC1L1 is a target of ezetimibe in
mice in addition to intestinal NPC1L1. This action of ezetimibe
may permit more biliary cholesterol to be excreted into bile, thus
promoting the ﬁnal step in the reverse cholesterol transport path-
way. But excess cholesterol build-up in the bile may negatively im-
pact health by leading to gallstone formation. An increase in
gallstone disease, however, was not observed in humans treated
with ezetimibe. Conversely, ezetimibe has been shown to prevent
cholesterol gallstone formation in mice [82], hamsters [83], and a
few human subjects [84]. Inter-individual variation exists in hepa-
tic [30] and perhaps intestinal NPC1L1 expression levels. The rela-
tive expression level of NPC1L1 in intestine and liver, and
differences in the ezetimibe efﬁciency in inhibiting intestinal cho-
lesterol absorption may ultimately determine whether ezetimibe
increases or decreases biliary cholesterol. In individuals with lower
expression of NPC1L1 in liver relative to intestine, if ezetimibe efﬁ-
ciently inhibits intestinal cholesterol absorption, it may actually
reduce the amount of cholesterol transported to the liver for hepa-
tobiliary secretion.
9. NPC1L1 and diseases
Cholesterol is an important biological component of cell mem-
branes, and is a precursor for bile acid and steroid hormone biosyn-thesis. However, high levels of blood cholesterol are associated
with atherosclerotic coronary heart disease. By lowering blood
cholesterol levels, NPC1L1 inhibition should have beneﬁcial effects
on this disease. Indeed, ezetimibe treatment reduces cholesterol
absorption, lowers plasma cholesterol, and inhibits the develop-
ment and progression of atherosclerosis in apolipoprotein (apo) E
knockout mice [85]. Likewise, NPC1L1/apoE double knockout mice
have a signiﬁcant reduction in cholesterol absorption and plasma
cholesterol levels, and almost complete protection from the devel-
opment of atherosclerosis [86]. In humans, ezetimibe mono-
therapy or coadministration with a statin signiﬁcantly reduces
blood LDL-C in primary hypercholesterolemic subjects [10]. A large
clinical trial, IMPROVE-IT (Improved Reduction of Outcomes: Vyto-
rin Efﬁcacy International Trial), is underway to determine whether
this reduction is translated to prevention of atherosclerosis and
cardiovascular events [10]. An earlier clinical trial ENHANCE (Eze-
timibe and Simvastatin in Hypercholesterolemia Enhances Athero-
sclerosis Regression) failed to show beneﬁt of Vytorin (ezetimibe
plus simvastatin) over simvastatin in improving the carotid artery
intima-media thickness (IMT), though the combined therapy ver-
sus statin alone resulted in more reduction in plasma LDL-C, in
720 heterozygous familial hypercholesterolemic patients who
had been treated with a statin prior to enrollment in the trial
[87]. But in this trial, patient selection and methodology may have
confounded the outcomes. The IMPROVE-IT trial should provide a
deﬁnitive answer to whether the combined therapy improves car-
diovascular events.
Unexpectedly, ezetimibe treatment or NPC1L1 deﬁciency was
recently shown to improve many metabolic disorders besides
hypercholesterolemia in rodents, although similar effects have
yet to be examined in humans. For instance, ezetimibe treatment
improved hepatic steatosis and insulin sensitivity in leptin recep-
tor-deﬁcient Zucker obese rats [88,89]. Ezetimibe also reduced he-
patic steatosis in mice on the methionine choline-deﬁcient diet
[90] or diets containing high amounts of cholesterol [91,92]. In a
study focusing on obesity and diabetes, ezetimibe treatment or
NPC1L1 deﬁciency was shown to attenuate weight gain and insulin
resistance in mice fed a high fat diet, though it remains to be
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sis [50]. In another study focusing on the role of NPC1L1 in protein
trafﬁcking and diet-induced hypercholesterolemia, NPC1L1 knock-
out mice were shown to be resistant to hepatic steatosis induced
by the Paigen diet, a lithogenic diet that contains high amounts
of bile acids plus cholesterol and fat [40]. Despite these interesting
observations, the mechanism by which NPC1L1 deﬁciency or eze-
timibe treatment alleviates hepatic steatosis, insulin resistance,
and obesity remain largely unexplored. Ezetimibe was reported
to decrease reactive oxygen species production, c-Jun N-terminal
kinase (JNK) activation, and endoplasmic reticulum stress in the
livers of Zucker obese fatty rats, as well as hepatocytes in vitro
[89], but it is unclear if this was a result of, or the mechanisms
for, reduced hepatic accumulation of cholesterol and fat in ezetim-
ibe-treated animals and hepatocytes. Nonetheless, the aforemen-
tioned ﬁndings together suggest that NPC1L1 plays an important
role in the pathogenesis of metabolic disorders, and its physiolog-
ical role extends beyond simple facilitation of intestinal cholesterol
absorption. Inhibition of NPC1L1 or NPC1L1-dependent intestinal
cholesterol absorption could be a potential preventative and ther-
apeutic approach for metabolic diseases such as non-alcoholic fatty
liver disease, insulin resistance, type 2 diabetes, and central
obesity.
10. Conclusions
NPC1L1 protein possesses multiple conserved domains, includ-
ing a SSD that is found in many other proteins involved in choles-
terol metabolism and regulation. NPC1L1 mediates intestinal
cholesterol absorption and it may also limit hepatobiliary choles-
terol excretion, particularly in humans. Thus, NPC1L1 may have
evolved to protect the body against excessive loss of cholesterol,
a structural component of the cell membrane. Evidence supports
NPC1L1 being the molecular target of ezetimibe. The potency of
ezetimibe in lowering blood cholesterol may be attributable to
its inhibition of NPC1L1 function in both the small intestine and li-
ver. Cell culture studies suggest that NPC1L1 may function as a
plasma membrane receptor for free cholesterol and the cellular ba-
sis for NPC1L1-dependent cholesterol uptake appears to be clath-
rin-mediated endocytosis. Future in vitro studies should focus on
whether NPC1L1 directly binds cholesterol and how this interac-
tion may affect NPC1L1/cholesterol endocytosis. Recently, NPC1L1
has been the focus of research beyond cholesterol absorption and
atherosclerosis. NPC1L1 inhibition showed beneﬁcial effects in ani-
mals on many components of the metabolic syndrome, such as
fatty liver, obesity, and insulin resistance. Future studies are
needed to dissect how NPC1L1 modulates the pathogenesis of met-
abolic diseases.
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